The spironolactone renaissance (Q33944169)

30 July 2017

1 reference

title

The spironolactone renaissance (English)

1 reference

30 July 2017

Doggrell SA

1

1 reference

30 July 2017

Brown L

series ordinal

2

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

10

1 reference

30 July 2017

issue

5

1 reference

30 July 2017

page(s)

943-954

1 reference

Primary aldosteronism: learning from the study of familial varieties

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.943

Induction of cardiac fibrosis by aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.943

Extra-adrenal mineralocorticoids and cardiovascular tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.943

Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.943

Increase in the basal tone of guinea pig thoracic aorta induced by ouabain is inhibited by spironolactone canrenone and potassium canrenoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.943

Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.943

Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.943

Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.943

Inverse relation between aldosterone and venous capacitance in chronically treated congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.943

Aldosterone and vascular damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.943

Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.943

Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.943

Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.943

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.943

Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.943

10.1517/13543784.10.5.943

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference